<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11062">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604851</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001316</org_study_id>
    <secondary_id>5U01HL080433-02</secondary_id>
    <secondary_id>SARCA</secondary_id>
    <nct_id>NCT00604851</nct_id>
  </id_info>
  <brief_title>Study of Acid Reflux Therapy for Children With Asthma</brief_title>
  <acronym>SARCA</acronym>
  <official_title>Study of Acid Reflux Therapy for Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchspasm,
      and increase airway reactivity. Children with asthma are often treated for GER with drugs to
      supress gastric acid production. However, this treatment is expensive, and with unproven
      benefit. The primary objective of this study is to conduct a multi-site, randomized,
      clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved
      proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly
      controlled asthma. The study will include 300 asthmatic children treated with inhaled
      corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms,
      excessive beta agonist use, or frequent exacerbations. Participants will be randomly
      assigned to treatment with either lansoprazole or placebo for 6 months. The presence,
      severity, and relationship of GER to asthma symptoms will be determined with 24 hour
      esophageal pH monitoring, but randomization to treatment will not be influenced by the
      presence or severity of GER. The primary outcome measure is the proportion of participants
      who have exacerbations of asthma defined by diaries and interviews. Secondary outcome
      measures include asthma symptom and control scores, GER symptoms, lung function, and
      unscheduled health care contacts. Pre-defined subgroup analyses will examine the
      relationship between specific clinical features and the response to lansoprazole. Treatment
      response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations,
      and related to polymorphisms in the gene CYP2C19, the cytochrome P450 pathway, and
      interleukin-1 (IL-1) beta, a pro-inflammatory cytokine. Tertiary studies will determine how
      the magnitude of GER impacts airways inflammation, as measured by the concentrations of
      hydrogen ions (pH) and nitric oxide in expired breath. The results of this trial sould have
      a major impact on the understanding and treatment of GER in children with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Asthma Control Questionnaire Score at the 24 Week Visit.</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Asthma Control Questionnaire contains 7 items that are scored on a 7 point scale (range is 0 to 6). The scores are then summed and divided by 7 to reveal an overall score. A lower score indicates better asthma control. The results reflect the difference in the Asthma Control Questionnaire Score between baseline (randomization visit) and 24 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom and Control Scores</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GER Symptoms</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled Heathcare Contacts</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants &lt;30 kg: 15 mg by mouth once daily; participants &gt;= 30 kg: 30 mg by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication taken by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>participants &lt; 30 kg: 15 mg by mouth once daily; participants &gt;= 30 kg: 30 mg by mouth once daily</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <other_name>brand name Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo medication taken by mouth once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No brand names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Age:

          -  6-16 years

          -  Asthma: Physician diagnosed asthma, mathacholine PC20&lt;16 mg/ml, treatment with a
             stable dose of daily inhaled corticosteroid equivalent to 200 micrograms/day of
             fluticasone or greater for 8 weeks or longer

          -  Poor asthma control: Use of beta-agonist for asthma symptoms twice/week or more,
             nocturnal awakening with asthma symptoms more than once per week, 2 or more emergency
             department, unscheduled physician visit, prednisone course, or hospitalizations for
             asthma in the past 12 months, Score of 1.5 or greater on the Juniper Scale of Recent
             Asthma Control

          -  Absence of GERD symptoms: No symptoms clearly attributed to GER at the time of
             enrollment.

        Exclusion Criteria:

          -  Surgery: Previous anti-reflux or peptic ulcer surgery, previous tracheo-esophageal
             fistula repair

          -  Pulmonary Function:FEV1 &lt;60% predicted normal as measured immediately before
             methacholine bronchoprovocation. Methacholine bronchoprovocation limited to
             participants with an FEV1 &gt;70% of predicted in accordance with FDA indication

          -  Other major chronic illnesses: Any major chronic illness including but not limited to
             non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell
             anemia, endocrine disease, congenital heart disease, congestive heart failure,
             stroke, severe hypertension, insulin-dependent diabetes mellitus, renal failure,
             liver disorders, immunodeficiency states, significant neurodevelopmental delay or
             behavioral disorders or other conditions that would interfere with participation in
             the study.

          -  Medication Use: Anti-reflux medication (proton pump inhibitors, H2 blockers,
             bethanecol, metaclopromide) within 1 month; Theophylline preparations, azoles,
             anti-coagulants, insulin, digitalis, any investigative drug within 2 months.

          -  Drug allergy: Previous adverse effects from lansoprazole, other proton pump
             inhibitors or methacholine challenge.

          -  Non-adherence: Inability or unwillingness of the legal guardian to provide consent or
             inability or unwillingness of the child to provide assent. Inability to swallow study
             medication. Inability to perform baseline measurements. Less than 80% completion of
             screening period diaries. Inability to contact by telephone. Intention to move out of
             the areqa within 6 months. No pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Teague, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Childrens Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2007</firstreceived_date>
  <firstreceived_results_date>July 10, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Anne M Fitzpatrick PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from medical clinics and community advertisements at the participating organizations.</recruitment_details>
      <pre_assignment_details>Children who met eligibility criteria underwent a 4-week screening period to determine whether they met pre-specified criteria for poor asthma control.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lansoprazole</title>
          <description>lansoprazole : participants &lt; 30 kg: 15 mg taken by mouth once daily, participants &gt;= 30 kg: 30 mg taken by mouth once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo medication, taken by mouth once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lansoprazole</title>
          <description>lansoprazole : participants &lt; 30 kg: 15 mg po once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo : participants &lt; 30 kg: 15 mg po once daily participants &lt;= 30 kg: 30 mg po once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="157"/>
                <measurement group_id="B3" value="306"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="157"/>
                <measurement group_id="B3" value="306"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11" spread="3"/>
                <measurement group_id="B2" value="11" spread="3"/>
                <measurement group_id="B3" value="11" spread="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
                <measurement group_id="B2" value="55"/>
                <measurement group_id="B3" value="118"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="188"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="157"/>
                <measurement group_id="B3" value="306"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Asthma Control Questionnaire Score at the 24 Week Visit.</title>
        <description>The Asthma Control Questionnaire contains 7 items that are scored on a 7 point scale (range is 0 to 6). The scores are then summed and divided by 7 to reveal an overall score. A lower score indicates better asthma control. The results reflect the difference in the Asthma Control Questionnaire Score between baseline (randomization visit) and 24 weeks of treatment.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole</title>
            <description>lansoprazole : participants &lt; 30 kg: 15 mg po once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo : participants &lt; 30 kg: 15 mg po once daily participants &lt;= 30 kg: 30 mg po once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="157"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Asthma Control Questionnaire Score at the 24 Week Visit.</title>
            <description>The Asthma Control Questionnaire contains 7 items that are scored on a 7 point scale (range is 0 to 6). The scores are then summed and divided by 7 to reveal an overall score. A lower score indicates better asthma control. The results reflect the difference in the Asthma Control Questionnaire Score between baseline (randomization visit) and 24 weeks of treatment.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  <measurement group_id="O2" value="1" lower_limit="0.9" upper_limit="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom and Control Scores</title>
        <time_frame>Baseline and 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GER Symptoms</title>
        <time_frame>Baseline and 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function</title>
        <time_frame>Baseline and 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unscheduled Heathcare Contacts</title>
        <time_frame>Baseline and 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lansoprazole</title>
          <description>lansoprazole : participants &lt; 30 kg: 15 mg po once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo : participants &lt; 30 kg: 15 mg po once daily participants &lt;= 30 kg: 30 mg po once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>W Gerald Teague</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-243-0613</phone>
      <email>wgt2p@hscmail.mcc.virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
